OpenVSafe by OpenVAERS
Search V-safe

6TZ-33067-77303

3 vaccinations 17 coded responses 38 check-ins 17 free-text entries 0 call cases
Sex
Male
Age at first dose
46-50
ZIP prefix
600 / IL
Registered
2021-02-09
Relationship
Self
Race
Asian
Ethnicity
Not Hispanic or Latino

Timeline

  1. 2021-02-09
    Registered in v-safe
  2. 2021-02-09
    Dose 1 — Pfizer-BioNTech
  3. 2021-02-09
    Health check-in — day 0, dose 1
    Feeling: Good · Site: Pain · None
    Adult check-in
  4. 2021-02-10
    Survey response — days 1–6 daily, dose 1
    MedDRA: Hyperglycaemia — Feeling: Fair · Site: Pain · Fatigue or tiredness · Be unable to do your normal daily activities
    Free text: Hyperglycemia, needed higher than usual insulin doses
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  5. 2021-02-11
    Survey response — days 1–6 daily, dose 1
    MedDRA: Hyperglycaemia, Type 1 diabetes mellitus — Feeling: Fair · Site: Pain · Fatigue or tiredness · Be unable to do your normal daily activities
    Free text: Hyperglycemia/ more than usual insulin demand
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  6. 2021-02-12
    Survey response — days 1–6 daily, dose 1
    MedDRA: Hyperglycaemia, Increased insulin requirement — Feeling: Fair · Fatigue or tiredness · Be unable to do your normal daily activities
    Free text: Still increased insulin demand (approx 30-40% higher than normal). Hyperglycemia
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  7. 2021-02-13
    Survey response — days 1–6 daily, dose 1
    MedDRA: Hyperglycaemia — Feeling: Fair · Site: Pain · Fatigue or tiredness
    Free text: Hyperglycemia
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  8. 2021-02-14
    Health check-in — days 1–6 daily, dose 1
    Feeling: Good · Fatigue or tiredness
    Adult check-in
  9. 2021-02-15
    Survey response — days 1–6 daily, dose 1
    MedDRA: Hyperglycaemia, Increased insulin requirement — Feeling: Good
    Free text: Slight hyperglycemia/ increased insulin demand
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  10. 2021-02-16
    Survey response — day 7, dose 1
    MedDRA: Blood insulin increased, Hyperglycaemia — Feeling: Good
    Free text: Hyperglycemia/ increased insulin demand
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  11. 2021-02-23
    Health check-in — day 14, dose 1
    Feeling: Good
    Adult check-in
  12. 2021-03-02
    Dose 2 — Pfizer-BioNTech
  13. 2021-03-02
    Health check-in — day 0, dose 2
    Feeling: Good · None
    Adult check-in
  14. 2021-03-03
    Survey response — days 1–6 daily, dose 2
    MedDRA: Increased insulin requirement, Type 1 diabetes mellitus — Feeling: Poor · Site: Pain · Chills, Muscle or body aches · Be unable to do your normal daily activities
    Free text: Increased insulin demand for type1 diabetes treatment
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  15. 2021-03-04
    Survey response — days 1–6 daily, dose 2
    MedDRA: Increased insulin requirement — Feeling: Fair · Site: Pain · Muscle or body aches · Be unable to do your normal daily activities
    Free text: Increased insulin demand
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  16. 2021-03-05
    Survey response — days 1–6 daily, dose 2
    MedDRA: Blood insulin increased — Feeling: Fair · Site: Pain · Fatigue or tiredness
    Free text: Increased insulin demand
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  17. 2021-03-06
    Survey response — days 1–6 daily, dose 2
    MedDRA: Condition aggravated, Pre-existing disease — Feeling: Good
    Free text: Still increased insulin demand
    MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
  18. 2021-03-07
    Health check-in — days 1–6 daily, dose 2
    Feeling: Fair · Fatigue or tiredness · Be unable to do your normal daily activities
    Adult check-in
  19. 2021-03-09
    Health check-in — day 7, dose 2
    Feeling: Good · None
    Adult check-in
  20. 2021-03-16
    Health check-in — day 14, dose 2
    Feeling: Good
    Adult check-in
  21. 2021-03-23
    Health check-in — day 21, dose 2
    Feeling: Good
    Adult check-in
  22. 2021-03-30
    Health check-in — day 28, dose 2
    Feeling: Good
    Adult check-in
  23. 2021-04-08
    Health check-in — day 35, dose 2
    Feeling: Good
    Adult check-in
  24. 2021-04-15
    Health check-in — day 42, dose 2
    Feeling: Good
    Adult check-in
  25. 2021-06-01
    Health check-in — 3 months, dose 2
    Feeling: Good
    Adult check-in
  26. 2021-08-31
    Health check-in — 6 months, dose 2
    Feeling: Good
    Adult check-in
  27. 2021-11-12
    Dose 3 — Pfizer-BioNTech
  28. 2021-11-12
    Health check-in — day 0, dose 3
    Feeling: Good · Site: Pain · None
    Adult check-in
  29. 2021-11-13
    Survey response — days 1–6 daily, dose 3
    MedDRA: Insulin resistance — Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activities
    Free text: Insulin resistance
    MedDRA releases: 2024-11 · check-in free text available
  30. 2021-11-14
    Survey response — days 1–6 daily, dose 3
    MedDRA: Insulin resistance — Feeling: Fair · Site: Pain · Fatigue or tiredness · Be unable to do your normal daily activities
    Free text: Insulin resistance
    MedDRA releases: 2024-11 · check-in free text available
  31. 2021-11-15
    Survey response — days 1–6 daily, dose 3
    MedDRA: Insulin resistance — Feeling: Fair · Site: Pain · Fatigue or tiredness
    Free text: Insulin resistance
    MedDRA releases: 2024-11 · check-in free text available
  32. 2021-11-16
    Survey response — days 1–6 daily, dose 3
    MedDRA: Insulin resistance — Feeling: Fair · Site: Pain · Fatigue or tiredness
    Free text: Still increased insulin resistance
    MedDRA releases: 2024-11 · check-in free text available
  33. 2021-11-17
    Survey response — days 1–6 daily, dose 3
    MedDRA: Insulin resistance — Feeling: Fair · Fatigue or tiredness
    Free text: Insulin resistance
    MedDRA releases: 2024-11 · check-in free text available
  34. 2021-11-18
    Survey response — days 1–6 daily, dose 3
    MedDRA: Insulin resistance — Feeling: Fair · Fatigue or tiredness
    Free text: Insulin resistance
    MedDRA releases: 2024-11 · check-in free text available
  35. 2021-11-26
    Health check-in — day 14, dose 3
    Feeling: Good
    Adult check-in
  36. 2021-12-03
    Health check-in — day 21, dose 3
    Feeling: Good
    Adult check-in
  37. 2021-12-12
    Health check-in — day 28, dose 3
    Feeling: Good
    Adult check-in
  38. 2021-12-17
    Health check-in — day 35, dose 3
    Feeling: Good
    Adult check-in
  39. 2021-12-24
    Health check-in — day 42, dose 3
    Feeling: Good
    Adult check-in
  40. 2022-02-11
    Health check-in — 3 months, dose 3
    Feeling: Good
    Adult check-in
  41. 2022-05-13
    Health check-in — 6 months, dose 3
    Feeling: Good
    Adult check-in
  42. 2022-11-12
    Survey response — 12 months, dose 3
    MedDRA: COVID-19 — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities
    Free text: Contracted COVID 19 infection about 3 weeks ago.
    MedDRA releases: 2024-11 · check-in free text available

Vaccinations

DoseDateManufacturerCo-administered
12021-02-09Pfizer-BioNTech
22021-03-02Pfizer-BioNTech
32021-11-12Pfizer-BioNTech No

Free text

Release 4 — days 1–6 daily, dose 1

2021-02-10

Systemic reaction (other): Hyperglycemia, needed higher than usual insulin doses

2021-02-11

Systemic reaction (other): Hyperglycemia/ more than usual insulin demand

2021-02-12

Systemic reaction (other): Still increased insulin demand (approx 30-40% higher than normal). Hyperglycemia

2021-02-13

Systemic reaction (other): Hyperglycemia

2021-02-15

Systemic reaction (other): Slight hyperglycemia/ increased insulin demand

Release 4 — day 7, dose 1

2021-02-16

Systemic reaction (other): Hyperglycemia/ increased insulin demand

Release 5 — days 1–6 daily, dose 2

2021-03-03

Systemic reaction (other): Increased insulin demand for type1 diabetes treatment

2021-03-04

Systemic reaction (other): Increased insulin demand

2021-03-05

Systemic reaction (other): Increased insulin demand

2021-03-06

Systemic reaction (other): Still increased insulin demand

Release 10 — days 1–6 daily, dose 3

2021-11-13

Systemic reaction (other): Insulin resistance

2021-11-14

Systemic reaction (other): Insulin resistance

2021-11-15

Systemic reaction (other): Insulin resistance

2021-11-16

Systemic reaction (other): Still increased insulin resistance

2021-11-17

Systemic reaction (other): Insulin resistance

2021-11-18

Systemic reaction (other): Insulin resistance

Release 12 — 12 months, dose 3

2022-11-12

Symptoms: Contracted COVID 19 infection about 3 weeks ago.

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

FieldPreferred term2021-092023-042024-11
SDCOVID-19 · · ✓
SROBlood insulin increased ✓ ✓ ✓
SROCondition aggravated ✓ ✓ ✓
SROHyperglycaemia ✓ ✓ ✓
SROIncreased insulin requirement ✓ ✓ ✓
SROInsulin resistance · · ✓
SROPre-existing disease ✓ ✓ ✓
SROType 1 diabetes mellitus ✓ ✓ ✓

✓ active code · ○ coded but marked inactive · blank = not in that release

Loading…